Wednesday, July 12, 2006

In a 13D filing released today on Xenogen Corp. (Nasdaq: XGEN), Millenco disclosed a 9.1% (1,864,495 shares) stake in the company. The firm notes that in February the company entered into a definitive Agreement and Plan of Merger with Caliper Life Sciences (Nasdaq: CALP). Millenco said it is continuing to evaluate its options with respect to the proposed merger.

NOTE: Shares of Xenogen are down from about $4 per share when the merger with CALP was announced to its current price of $2.50. The stock was at $2.89 before the merger was announced.